Future investigations should therefore examine TSP1–CD47 signaling in greater detail and explore additional molecular mechanisms, as elucidating these pathways will be essential for developing effective therapies for the PVOD. This evidence concerns the gene CD47 and pulmonary venoocclusive disease.